SOLICITATION NOTICE
68 -- Assays
- Notice Date
- 8/14/2012
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(TR)-2012-250-RSF
- Archive Date
- 9/4/2012
- Point of Contact
- Rashida S. Ferebee, Phone: 3014352605
- E-Mail Address
-
ferebeers@nhlbi.nih.gov
(ferebeers@nhlbi.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSALS. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisition (OA) on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Life Technologies, 3175 Staley Road, Grand Island, New York 140722. The following items will be purchased: 1. Part Number K1030, LIVEBLAZER FRET B/G LOADING 5 MG, Quantity, 20. The CCF4-AM substrate is essential assay components for the GeneBLAzer® platform. NCATS currently has approximately thirty assays that use this reagent. The homogenous assay minimizes the number of reagent addition steps in the assay and is adapted easily to higher throughput applications being simple and fast. Going forward, it was found that this reagent worked best in NCATS preliminary screens and NCATS project data has now been based on the test results that were established using this product. We concluded that all upcoming screens would be standardized by using the same reagent and that the upcoming screening will be performed with CCF4-AM substrate. In order to avoid the introduction of new variables into our ongoing data and the numerous upcoming screens, NCATS must continue to use the same protocols that have been established using this CCF4-AM substrate reagent. This product is trade mark protected and is not distributed to any other vendors. This is a sole source purchase as this product is only available from Life Technologies. This acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, and is exempt from the requirements of FAR Part 6, Competition Requirements. The North American Industry Classification Code (NAICS) is 325413 and the Size Standard is 500 Employees. This notice of intent is not a request for competitive proposals. The determination by the Government not to compete the proposed purchase order based upon responses to this notice is solely within the discretion of the Government. Interested parties may identify their interest and capabilities in response to this requirement. Comments to this announcement, referencing synopsis number NHLBI-CSB-(TR)-2012-250-RSF may be submitted by mail to the National Heart, Lung and Blood Institute, Office of Acquisitions, 6701 Rockledge Drive, Suite 6145, Bethesda, MD 20892-7902, Attention: Rashida Ferebee, or by email to ferebeers@nhlbi.nih.gov. Interested parties responding to this announcement need to do so by 9:00am Eastern Standard Time on August 20, 2012.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(TR)-2012-250-RSF /listing.html)
- Place of Performance
- Address: NIH/NCATS, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN02839545-W 20120816/120815001435-6b21563c3b8880fd0d0137619e33d229 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |